Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
02268 WUXI XDC
RT Nominal down31.550 -0.150 (-0.473%)
藥明合聯生物技術有限公司
WUXI XDC CAYMAN INC.
Financial Year (D/M)01/01 - 31/12
Listing Date17/11/2023
Listing Price (HKD)20.600
Market Cap (HKD)37.852 Billions
Shares Capital
Issued Share Capital1,199,736,604
Market Value Indicator (Latest)
Year (Currency)2024/06 - Interim (RMB)
EPS (RMB)41.000 cts
DPS (RMB)0.000 cts
Divpayout Ratio (%)--
Cashflowper Share ($)--
BNV (RMB)5.000 dollar
Market Value Indicator (Year)
Peratio104.2
Yield (%)--
Pricetobook Ratio6.409
Remarks:  Real time quote last updated: 24/12/2024 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service.
Security Code
Company Name (Chi/Eng/Keywords)
Industry
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.